X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (142) 142
index medicus (116) 116
oncology (110) 110
female (71) 71
male (67) 67
lung cancer (63) 63
aged (60) 60
middle aged (57) 57
adult (54) 54
chemotherapy (53) 53
respiratory system (51) 51
lung neoplasms - drug therapy (49) 49
cancer (45) 45
lung neoplasms - pathology (44) 44
carcinoma, non-small-cell lung - drug therapy (41) 41
care and treatment (39) 39
aged, 80 and over (37) 37
cough (33) 33
survival (31) 31
lung neoplasms - genetics (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
carcinoma, non-small-cell lung - pathology (24) 24
lung cancer, non-small cell (23) 23
research (23) 23
treatment outcome (23) 23
tumors (23) 23
animals (22) 22
carcinoma, non-small-cell lung - genetics (22) 22
evidence-based medicine (22) 22
gefitinib (22) 22
mutation (22) 22
patients (22) 22
analysis (21) 21
pulmonary/respiratory (21) 21
disease-free survival (20) 20
lung neoplasms - mortality (20) 20
abridged index medicus (19) 19
metastasis (19) 19
prognosis (19) 19
small cell lung cancer (19) 19
antineoplastic agents - therapeutic use (18) 18
diagnosis (18) 18
hematology, oncology and palliative medicine (18) 18
non-small cell lung cancer (17) 17
cell lung-cancer (16) 16
clinical trials (16) 16
lung neoplasms - therapy (16) 16
protein kinase inhibitors - therapeutic use (16) 16
risk factors (16) 16
carcinoma, non-small-cell lung - mortality (15) 15
critical care medicine (15) 15
radiotherapy (15) 15
usage (15) 15
cancer therapies (14) 14
carcinoma (14) 14
guidelines (14) 14
neoplasm staging (14) 14
quality of life (14) 14
small cell lung carcinoma - pathology (14) 14
cell line, tumor (13) 13
expression (13) 13
lung neoplasms - metabolism (13) 13
mice (13) 13
nsclc (13) 13
peripheral-blood (13) 13
therapy (13) 13
carboplatin (12) 12
cough - etiology (12) 12
health aspects (12) 12
mutations (12) 12
neoplastic cells, circulating - pathology (12) 12
adenocarcinoma (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
apoptosis (11) 11
cisplatin (11) 11
combination (11) 11
disease progression (11) 11
docetaxel (11) 11
genetic aspects (11) 11
medicine & public health (11) 11
open-label (11) 11
pharmacology & pharmacy (11) 11
young adult (11) 11
antineoplastic agents - administration & dosage (10) 10
biomarkers (10) 10
biomarkers, tumor - blood (10) 10
biopsy (10) 10
egfr (10) 10
gemcitabine (10) 10
kaplan-meier estimate (10) 10
neoplastic cells, circulating - metabolism (10) 10
non-small-cell lung cancer (10) 10
respiratory tract diseases (10) 10
article (9) 9
cisplatin - administration & dosage (9) 9
clinical trials as topic (9) 9
crizotinib (9) 9
epidermal growth factor (9) 9
immunotherapy (9) 9
lung cancer, small cell (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Arce Vargas, Frederick and Furness, Andrew J.S and Solomon, Isabelle and Joshi, Kroopa and Mekkaoui, Leila and Lesko, Marta H and Miranda Rota, Enrique and Dahan, Rony and Georgiou, Andrew and Sledzinska, Anna and Ben Aissa, Assma and Franz, Dafne and Werner Sunderland, Mariana and Wong, Yien Ning Sophia and Henry, Jake Y and O’Brien, Tim and Nicol, David and Challacombe, Ben and Beers, Stephen A and Spain, Lavinia and Wotherspoon, Andrew and Francis, Nicholas and Smith, Amy and Smith, Sean and Smith, Myles and Smith, Elaine and Strauss, Dirk and Hayes, Andrew and Soultati, Aspasia and Stares, Mark and Lynch, Joanna and Fotiadis, Nicos and Fernando, Archana and Hazell, Steve and Chandra, Ashish and Pickering, Lisa and Rudman, Sarah and Chowdhury, Simon and Swanton, Charles and Jamal-Hanjani, Mariam and Veeriah, Selvaraju and Shafi, Seema and Czyzewska-Khan, Justyna and Johnson, Benjamin and Johnson, Diana and Laycock, Joanne and Bosshard-Carter, Leticia and Goh, Gerald and Rosenthal, Rachel and Gorman, Pat and Murugaesu, Nirupa and Hynds, Robert E and Wilson, Gareth and Birkbak, Nicolai J and Watkins, Thomas B.K and McGranahan, Nicholas and Horswell, Stuart and Mitter, Richard and Escudero, Mickael and Stewart, Aengus and Van Loo, Peter and Rowan, Andrew and Xu, Hang and Turajlic, Samra and Hiley, Crispin and Abbosh, Christopher and Goldman, Jacki and Stone, Richard Kevin and Denner, Tamara and Matthews, Nik and Matthews, Sue and Elgar, Greg and Ward, Sophia and Biggs, Jennifer and Costa, Marta and Begum, Sharmin and Phillimore, Ben and Chambers, Tim and Nye, Emma and Graca, Sofia and Al Bakir, Maise and Hartley, John A and Lowe, Helen L and Herrero, Javier and Lawrence, David and Hayward, Martin and Panagiotopoulos, Nikolaos and Kolvekar, Shyam and Falzon, Mary and Borg, Elaine and Simeon, Celia and Hector, Gemma and Aranda, Marie and Novelli, Marco and Oukrif, Dahmane and Janes, Sam M and Thakrar, Ricky and Forster, Martin and Ahmad, Tanya and Lee, Siow Ming and ... and Melanoma TRACERx Consortium and Renal TRACERx Consortium and Lung TRACERx Consortium
Immunity, ISSN 1074-7613, 04/2017, Volume 46, Issue 4, pp. 577 - 586
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies... 
regulatory T cells | tumor immunotherapy | anti-CD25 | Treg depletion | inhibitory Fc receptor | CD25 | tumor microenvironment | Fc gamma receptors | anti-PD-1 | EFFECTOR | RESPONSES | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | CANCER-PATIENTS | MELANOMA | MONOCLONAL-ANTIBODY | ANTI-CTLA-4 ANTIBODIES | IMMUNOLOGY | ANTITUMOR-ACTIVITY | COMBINATION | GAMMA-RS | T-Lymphocytes, Regulatory - metabolism | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lymphocyte Depletion | Receptors, IgG - metabolism | T-Lymphocytes, Regulatory - immunology | Neoplasms - therapy | Flow Cytometry | Immunoglobulin Fc Fragments - immunology | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - immunology | Kaplan-Meier Estimate | Programmed Cell Death 1 Receptor - metabolism | Receptors, IgG - immunology | Protein Binding - immunology | Animals | Neoplasms - immunology | K562 Cells | Cell Line, Tumor | Mice | Antibodies, Monoclonal - metabolism | Programmed Cell Death 1 Receptor - immunology | Neoplasms - pathology | Viral antibodies | Cell death | Analysis | Immunotherapy | Antibodies | T cells | Cancer | Fc receptors | Beer | Immunoglobulins | Lymphatic system | Immune response | Cytokines | Melanoma | Light emitting diodes | Lymphocytes T | Anticancer properties | Depletion | Lymphocytes | Tumors | Immune system | Report
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1116 - 1125
Journal Article
by Abbosh, Christopher and Birkbak, Nicolai J and Wilson, Gareth A and Jamal-Hanjani, Mariam and Constantin, Tudor and Salari, Raheleh and Le Quesne, John and Moore, David A and Veeriah, Selvaraju and Rosenthal, Rachel and Marafioti, Teresa and Kirkizlar, Eser and Watkins, Thomas B. K and McGranahan, Nicholas and Ward, Sophia and Martinson, Luke and Riley, Joan and Fraioli, Francesco and Al Bakir, Maise and Grönroos, Eva and Zambrana, Francisco and Endozo, Raymondo and Bi, Wenya Linda and Fennessy, Fiona M and Sponer, Nicole and Johnson, Diana and Laycock, Joanne and Shafi, Seema and Czyzewska-Khan, Justyna and Rowan, Andrew and Chambers, Tim and Matthews, Nik and Turajlic, Samra and Hiley, Crispin and Lee, Siow Ming and Forster, Martin D and Ahmad, Tanya and Falzon, Mary and Borg, Elaine and Lawrence, David and Hayward, Martin and Kolvekar, Shyam and Panagiotopoulos, Nikolaos and Janes, Sam M and Thakrar, Ricky and Ahmed, Asia and Blackhall, Fiona and Summers, Yvonne and Hafez, Dina and Naik, Ashwini and Ganguly, Apratim and Kareht, Stephanie and Shah, Rajesh and Joseph, Leena and Quinn, Anne Marie and Crosbie, Phil A and Naidu, Babu and Middleton, Gary and Langman, Gerald and Trotter, Simon and Nicolson, Marianne and Remmen, Hardy and Kerr, Keith and Chetty, Mahendran and Gomersall, Lesley and Fennell, Dean A and Nakas, Apostolos and Rathinam, Sridhar and Anand, Girija and Khan, Sajid and Russell, Peter and Ezhil, Veni and Ismail, Babikir and Irvin-Sellers, Melanie and Prakash, Vineet and Lester, Jason F and Kornaszewska, Malgorzata and Attanoos, Richard and Adams, Haydn and Davies, Helen and Oukrif, Dahmane and Akarca, Ayse U and Hartley, John A and Lowe, Helen L and Lock, Sara and Iles, Natasha and Bell, Harriet and Ngai, Yenting and Elgar, Greg and Szallasi, Zoltan and Schwarz, Roland F and Herrero, Javier and Stewart, Aengus and Quezada, Sergio A and Peggs, Karl S and Van Loo, Peter and Dive, Caroline and Lin, C. Jimmy and Rabinowitz, Matthew and Aerts, Hugo J. W. L and ... and TRACERx Consortium and The PEACE Consortium and TRACERx consortium and PEACE consortium and The PEACE consortium and The TRACERx consortium
Nature, ISSN 0028-0836, 04/2017, Volume 545, Issue 7655, pp. 446 - 451
Journal Article
Nature Communications, ISSN 2041-1723, 11/2016, Volume 7, Issue 1, p. 13322
Journal Article
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 07/2019, Volume 121, Issue 3, pp. 197 - 198
Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered 'undruggable'. In 2019, we will see the first clinical... 
ONCOLOGY | CANCER | KRAS | Inhibitors | Targeted therapies | Non-small-cell lung cancer | Tumour biomarkers | Cancer genetics
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article